Method of treating systemic lupus erythematosus
Patent disclosure · 2000
- What the patent describes
- Same 61-patient lupus program as the 1999 publication; all Bemitil arms also received glucocorticoids.
- Reported evidence
- The patent describes four treatment groups using glucocorticoids with or without cyclophosphamide and Bemitil. It reports improvements in selected clinical and laboratory signs and anti-DNA antibodies in the Bemitil groups. This appears to describe the same research program as the 1999 paper.
Reported patent results
Reported findings
The patent reports lower anti-DNA antibodies and steroid changes in adjunctive Bemitil arms of the historical lupus program; unequal groups and follow-up prevent a causal efficacy estimate.
Same 61-patient lupus program as the 1999 publication; all Bemitil arms also received glucocorticoids.
Population or model Same 61-patient lupus program as the 1999 publication; all Bemitil arms also received glucocorticoids.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Anti-DNA antibodies | Reported within-group reductions in both Bemitil-containing arms | p<0.001 |
| Mean daily prednisolone, group 3 | 23.5 → 18.7 mg/day during observation | |
| Mean daily prednisolone, group 1 | 14.7 → 29.0 mg/day during observation | |
| Reported relapses / exacerbations | 11/30 without Bemitil at 6–12 months; 5/31 with Bemitil at 12–18 months |
Historical treatment observations, not dosing advice. Unequal follow-up, baseline severity and treatment selection preclude a causal steroid-sparing claim or comparative relapse-risk calculation. Patent and paper are not independent replication.
Source for these results ↗ · Reviewed 2026-11-05
Patent claims and provenance
Use. Bemitil as an adjunct to glucocorticoids, with or without cyclophosphamide, in lupus. The patent and 1999 publication describe the same research program, not independent replications.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2157684C2 ↗ · 2000-10-20
- Earliest priority / filing
- 1997-12-22 / 1997-12-22
- Original applicant / assignee
- Научно-исследовательский институт фармакологии Российской академии медицинских наук
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20200796 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Agent for treatment of patients with systemic lupus erythematosis
Inventors: Т.А. Лисицына; А.Д. Дурнев; М.М. Иванова; С.Б. Середенин; В.А. Насонова.
Study limitations and source details
Study limitations
- Patent reproduction; allocation concealment and blinding are not established. Treatment choice also reflected disease severity.
- Numerous outcomes and unequal follow-up periods prevent a simple comparative relapse-rate interpretation.
- Not an MS study or independent confirmation of the 1999 SLE report.
Related publications may describe some of the same participants or experiments.
Source details
Russian patent with English translation
The summary reflects the results reported in the cited source.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
T. A. Lisitsyna and colleagues. Method of treating systemic lupus erythematosus RU2157684C2. Filed 22 December 1997; published 20 October 2000